Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBITDA (2016 - 2025)

Historic EBITDA for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$101.0 million.

  • Intellia Therapeutics' EBITDA rose 2306.34% to -$101.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$448.1 million, marking a year-over-year increase of 1341.6%. This contributed to the annual value of -$518.3 million for FY2024, which is 888.7% down from last year.
  • As of Q3 2025, Intellia Therapeutics' EBITDA stood at -$101.0 million, which was up 2306.34% from -$101.7 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' EBITDA peaked at -$46.2 million during Q1 2021, and registered a low of -$152.3 million during Q1 2022.
  • For the 5-year period, Intellia Therapeutics' EBITDA averaged around -$108.4 million, with its median value being -$111.5 million (2022).
  • As far as peak fluctuations go, Intellia Therapeutics' EBITDA tumbled by 22952.96% in 2022, and later soared by 3542.9% in 2023.
  • Intellia Therapeutics' EBITDA (Quarter) stood at -$83.7 million in 2021, then plummeted by 33.22% to -$111.5 million in 2022, then dropped by 17.35% to -$130.8 million in 2023, then decreased by 0.57% to -$131.6 million in 2024, then grew by 23.26% to -$101.0 million in 2025.
  • Its last three reported values are -$101.0 million in Q3 2025, -$101.7 million for Q2 2025, and -$113.9 million during Q1 2025.